Home›Trial›NCT06804811
🔬NCT06804811Phase 3RECRUITING

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Study Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

Conditions
NonSegmental Vitiligo
Interventions / Drugs
Ruxolitinib CreamVehicle Cream
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
C60/100
Study Details
Enrollment250 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647310+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.